Dynamic receptor-based pharmacophore model development and its application in designing novel HIT-1 integrase inhibitors

被引:66
作者
Deng, JX
Lee, KW
Sanchez, T
Cui, M
Neamati, N
Briggs, JM
机构
[1] Univ So Calif, Sch Pharm, Dept Pharmaceut Sci, Los Angeles, CA 90089 USA
[2] Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA
[3] Univ Houston, Dept Chem Engn, Houston, TX 77204 USA
关键词
D O I
10.1021/jm049410e
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
We present here a dynamic receptor-based pharmacophore model representing the complementary features of the active site region of HIV-1 integrase (IN), which was developed from a series of representative conformations of IN. Conformations of IN were sampled through a molecular dynamics study of the catalytic domain of an IN monomer, and an ensemble of representative IN structures were collected via a probability-based representative conformer sampling method that considers both the potential energy and the structural similarity of the protein conformations. The dynamic pharmacophore model was validated by a set of 128 known inhibitors, and the results showed that over 72% of the active inhibitors (IC50 lower than 20 muM) could be successfully identified by the dynamic model. Therefore, we screened our in-house database of commercially available compounds against this model and successfully identified a set of structurally novel IN inhibitors. Compounds 7 and 18 with IC(50)s of 8 muM and 15 muM, respectively, against the strand transfer reaction were the most potent. Moreover, 7, 8 and 20 showed a 5-fold selectivity for the strand transfer reaction over X-processing.
引用
收藏
页码:1496 / 1505
页数:10
相关论文
共 46 条
[1]
*ACC INC, CAT 4 6
[2]
Developing a dynamic pharmacophore model for HIV-1 integrase [J].
Carlson, HA ;
Masukawa, KM ;
Rubins, K ;
Bushman, FD ;
Jorgensen, WL ;
Lins, RD ;
Briggs, JM ;
McCammon, JA .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (11) :2100-2114
[3]
Chen I.-Jen, 2002, Current Drug Targets - Infectious Disorders, V2, P217, DOI 10.2174/1568005023342380
[4]
COFFIN IM, 1997, RETROVIRUSES
[5]
Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update [J].
Dayam, R ;
Neamati, N .
CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (22) :1789-1802
[6]
INHIBITION OF HIV-1 INTEGRASE BY FLAVONES, CAFFEIC ACID PHENETHYL ESTER (CAPE) AND RELATED-COMPOUNDS [J].
FESEN, MR ;
POMMIER, Y ;
LETEURTRE, F ;
HIROGUCHI, S ;
YUNG, J ;
KOHN, KW .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (03) :595-608
[7]
Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design [J].
Goldgur, Y ;
Craigie, R ;
Cohen, GH ;
Fujiwara, T ;
Yoshinaga, T ;
Fujishita, T ;
Sugimoto, H ;
Endo, T ;
Murai, H ;
Davies, DR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (23) :13040-13043
[8]
Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium [J].
Goldgur, Y ;
Dyda, F ;
Hickman, AB ;
Jenkins, TM ;
Craigie, R ;
Davies, DR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (16) :9150-9154
[9]
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells [J].
Hazuda, DJ ;
Felock, P ;
Witmer, M ;
Wolfe, A ;
Stillmock, K ;
Grobler, JA ;
Espeseth, A ;
Gabryelski, L ;
Schleif, W ;
Blau, C ;
Miller, MD .
SCIENCE, 2000, 287 (5453) :646-650
[10]
Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore [J].
Hong, H ;
Neamati, N ;
Winslow, HE ;
Christensen, JL ;
Orr, A ;
Pommier, Y ;
Milne, GWA .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1998, 9 (06) :461-472